tbuckley/cabot-search huggingface dataset:
심혈관계 위험인자로서의 비알코올지방간질환; 경동맥 동맥경화와의 상관관계
Authors: 최수연 ( Su Yeon Choi ), 김동희 ( Dong Hee Kim ), 강진화 ( Jin Hwa Kang ), 박민정 ( Min Jung Park ), 김영선 ( Young Sun Kim ), 임선희 ( Seon Hee Lim ), 김충현 ( Chung Hyeon Kim ), 이효석 ( Hyo Suk Lee ), Su Yeon Choi, Dong Hee Kim, Jin Hwa Kang, Min Jung
Journal: Clinical and Molecular Hepatology (2008)

목적 : 비 알코올지 방간질환(Non-alcoholic fatty liver disease, NAFLD)은 비만, 고지혈증, 언슐린저항성, 제2형 당뇨병 등과 밀접히 연관되어 있고, 이는 NAFLD가 대사증후군의 하나의 간내 발현일수 있음을 시사한다. 이와 같은 NAFLD와 대사증후군의 상호연관성에 대한 관섬이 증가되어 가면서 대사증후군이 심혈관계 질환의 위험성을 증가시키듯 NAFLD의 존재가 섬혈관계 질환의 위험인 자가 된다는 다수의 연구 결과들이 있다. 본 연구는 잠재적인 동맥경화를 진단하는 비침습적인 검사인 경동맥초음파검사를 통한 경동맥 내중막 두께와 경동맥 플라크의 유무를 NAFLD군과 정상군 사이에 비교 분석하여 NAFLD가 섬혈관계 질환의 위험인자인지를 알아보고자 하였다. 대상과 방법: 2005년 1월부터 ``2fff1년 8월까지 서울대학교병원 강남센터에서 복부초음파와 경동맥초음파검사를 시행하고 연구에 동의한 823명 중 알코올 음주력과 심혈관계 질환의 과거력이 없고 혈청검사로 B형, C형간염 이 없는 659명을 대상으로 하였다. NAFLD군과 정상군의 체질량지수, 허리둘레, 혈압, 간기능 검사와 지질검사, 인슐린, 기타 심혈관계 위험인자를 측정하였고, 양 군 간에 경동맥초음파검사를 통해 구한 내중막 두께와 경동맥 플라크 유무를 비교하였다. 결과: NAFLD군은 314명(47.6%)이고 정상군은 345명이었다. 양 군 간에 유의한 차이를 보인 인구학적, 생화학적 인자들로는 수축기혈압, 이완기 혈압, 체질량지수, 허리둘레, AST, ALT, γ-GT, 요산, 총 콜레스테롤, 중성지방, 고밀도지질단백 콜레스테롤, 공복혈당, 공복인슐린,HOMA지수, 당화혈색소, PAI-1이었다. 양군간에 경동맥 내중막 두께의 평균을 비교하면 NAFLD군이 0.817±0.212 mIll이고 대조군이 0.757±0.198 mm로 통계 적으로 유의한 차이를 보였다(p<o.oo1) 경동맥 플라크의 경우 NAFLD군에서는 26.4%에서 플라크가 존재하였으며 대조군에서는 15.9%에서 플라크 가 존재하여 양 군에서 유의한 차이를 보였다 (p<o.oo1), 성별, 나이, 체질량지수와 대사증후군의 모든 인자를 보정하여 시행한 다중 로지스틱 회귀분석에서 나이, NAFLD, 대사증후군의 인자 중혈압 상승과 공복혈당의 상승이 경동맥 동맥경화 와 의미 있는 연관성을 보였다. 결론: NAFLD는 대사증후군과 유의한 연관성이 있었으며, 이러한 대사증후군과 상관관계를 보정한 후에도 NAFLD 군에서 정상군에 비해 경동맥 내중막 두께가 증가하고 경동맥 플라크의 발생빈도가 높은 결과를 보였다. 그러므로 NAFLD는 섬혈관계 질환의 독립적 인 위험인자로 고려할 수 있겠다.
HIV-Positive–to–HIV-Positive Kidney Transplantation
Authors: Guillaume Canaud, Veronique Avettand-Fenoel, Christophe Legendre
Journal: New England Journal of Medicine (2015)

BACKGROUND-The outcome of kidney transplantation in human immunodeficiency virus (HIV)-positive patients who receive organs from HIV-negative donors has been reported to be similar to the outcome in HIV-negative recipients.We report the outcomes at 3 to 5 years in HIVpositive patients who received kidneys from HIV-positive deceased donors.METHODS-We conducted a prospective, nonrandomized study of kidney transplantation in HIV-infected patients who had a CD4 T-cell count of 200 per cubic millimeter or higher and an undetectable plasma HIV RNA level.All the patients were receiving antiretroviral therapy (ART).The patients received kidneys from deceased donors who tested positive for HIV with the use of fourth-generation enzyme-linked immunosorbent assay at the time of referral.All the donors either had received no ART previously or had received only first-line ART. RESULTS-FromSeptember 2008 through February 2014, a total of 27 HIV-positive patients underwent kidney transplantation.Survivors were followed for a median of 2.4 years.The rate of survival among the patients was 84% at 1 year, 84% at 3 years, and 74% at 5 years.The corresponding rates of graft survival were 93%, 84%, and 84%.(If a patient died with a functioning graft, the calculation was performed as if the graft had survived.)Rejection rates were 8% at 1 year and 22% at 3 years.HIV infection remained well controlled, with undetectable virus in blood after the transplantation. CONCLUSIONS-Kidneytransplantation from an HIV-positive donor appears to be an additional treatment option for HIV-infected patients requiring renal-replacement therapy.(Funded by Sanofi South Africa and the Roche Organ Transplantation Research Foundation.)South africa has one of the highest incidences of human immunodeficiency virus (HIV) infection in Africa.The rollout of antiretroviral therapy (ART) in South Africa has been tremendously successful in extending the lives of HIV-infected persons.Consequently, more
Abstract 4075: Role of yes-associated protein 1 (YAP1) in human pancreatic ductal adenocarcinoma initiation and progression
Authors: Xue Yin, Jun Liu, Naoki Akanuma, Michael Nipper, Pei Wang
Journal: Cancer Research (2018)

Abstract Introduction: Understanding the molecular mechanisms underlying pancreatic ductal adenocarcinoma (PDAC) initiation and progression is an urgent need to achieve more effective diagnosis and treatment to this deadly cancer. We have developed a flow cytometry-based, high resolution lineage tracing method and 3D culture system to study PDAC initiation and progression using normal human pancreatic cells. Methods: Normal human acinar cells or cells undergoing acinar-to-ductal metaplasia (ADM, AD cells) are isolated by fluorescence-activated cell sorting (FACS), and cultured in 3D-culture system. Lentivirus carrying either YAP1-mCherry are transduced into acinar cells to study whether YAP1 is sufficient to induce ADM or is required during TGFβ-induced ADM. Lentivirus carrying either shYAP1-mCherry or shYAP1-KrasG12D-mCherry are transduced into AD cells to study whether YAP1 is required for AD cell proliferation and Kras-induced prolonged proliferation. ChIP-PCR and genome-wide ChIP-seq will be used to identify the mechanism through which YAP1 promotes PDAC development and progression. Lentivirus carrying inducible shYAP1 will be transduced into cancer producing, engineered AD cells and orthotopically transplanted into SCID mice to investigate whether inhibiting YAP1 could suppress PDAC progression. Results: We already found that TGFβ could induce ADM and oncogenic Kras could maintain the proliferation capacity of AD cells. Also, TGFβ induces YAP1 expression and TGFβ inhibitor blocks YAP1 induction during ADM process, and deleting YAP1 will suppress Kras-induced over-proliferation in AD cells, suggesting that YAP1 plays an important role in ADM, and is downstream of TGFβ as well as Kras signaling. Conclusion and significance: Successful completion of the project will give us a better understanding of how YAP1 functions in human PDAC initiation and progression. It will provide us opportunities to develop new methods for early detection and treatment of PDAC. Citation Format: Xue Yin, Jun Liu, Naoki Akanuma, Michael Nipper, Pei Wang. Role of yes-associated protein 1 (YAP1) in human pancreatic ductal adenocarcinoma initiation and progression [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 4075.
‘Only by speaking out can we create lasting change’: what can we learn from the Dr Larry Nassar tragedy?
Authors: Margo Mountjoy
Journal: British Journal of Sports Medicine (2018)

> As it turns out… Dr Nassar was not a doctor, he in fact is, was, and forever shall be, a child molester and a monster of a human being. End of story. He abused my trust, he abused my body and he left scars on my psyche that may never go away.
> 
> McKayla Maroney, Olympic Gold Medallist, London 2012.
Dr Larry Nassar was sentenced on 24 January 2018 to 40–125 years in prison in Eaton County and 40–175 years in Ingham County, Michigan, USA, for first-degree criminal sexual conduct in addition to 60 years in Federal court for child pornography. During the court proceedings, 156 women who call themselves the ‘army of survivors’, spoke about their abuse experiences in emotional and powerful victim impact statements. In the course of his professional career, Dr Nassar is alleged to have sexually abused approximately 256 female athletes from 1998 to 2015, often in front of parents. His victims were mainly gymnasts, some as young as 6 years of age. For some victims, the abuse occurred repetitively, up to 10 years in duration. Dr Nassar stated that his ‘medical treatments’ (which were invasive pelvic floor ‘therapy’ where he would digitally penetrate girls’ vaginas and anuses) would cure physical injuries. He abused them in his clinic, his home, at training camps and at competition venues where he treated them alone in his hotel room, often after having sedated the athlete with sleeping pills. Dr Nassar referred to himself as the ‘body whisperer’.1 

What is unique about this sexual abuse case is that Dr Nassar is an osteopathic sport medicine physician. One of our colleagues. One of our fraternity. Larry was the physician for the USA Gymnastics team and worked at four Olympic Games. He was a practising sport medicine physician for a prestigious university in the NCAA collegiate system in the USA, …
Selective self-induced stimulus amplification prodrug platform for inhibiting multidrug resistance and lung metastasis
Authors: Chenfeng Xu, Yu Sun, Yan Qi, Yulin Yu, Yangzhou He, Mei Hu, Qian Hu, Tingting Wu, Dan Zhang, Lihuan Shang, Huan Deng, Zhiping Zhang
Journal: Journal of Controlled Release (2018)
Lung cancer CT screening: are we ready to consider screening biennially in a subgroup of low-risk individuals?
Authors: John K Field, Stephen W Duffy
Journal: Thorax (2018)

Most published research on low-dose CT screening for lung cancer pertains to annual screening.1 Schreuder and colleagues explore the possibilities for extending the interscreening interval on an individual basis.2 Using data from the US National Lung Screening Trial,3 they build up a logistic regression model of risk of a lung cancer at the second annual screen or in the year following it, based on subject characteristics and radiological observations including nodule attributes at the first screen. The logistic model incorporates polynomial regression coefficients where appropriate. They compare their model with other possible prediction models for this specific endpoint and find it to be superior.

The authors conclude that there is scope for extending the interval for some screenees. From their model, they project that for different risk thresholds, at the second screen, 2558 (10.4%), 7544 (30.7%), 10 947 (44.6%), 16 710 (68.1%) and 20 023 (81.6%) of the 24 368 screens could have been omitted, at the cost of delayed diagnosis of 0 (0.0%), 8 (4.6%), 17 (9.8%), 44 (25.3%) and 70 (40.2%) of the 174 lung cancers, respectively.

These observations …
Abstract 12984: Long-term Therapy With Elamipretide Normalizes Protein Levels of the Signal Transducer and Activator of Transcription 3 (STAT3) in Mitochondria of Left Ventricular Myocardium of Dogs With Chronic Heart Failure
Authors: Ramesh C Gupta, Vinita Singh-Gupta, Kefei Zhang, Jiang Xu, Hani N Sabbah
Journal: Circulation (2016)

Introduction: The signal transducer and activator of transcription 3 (STAT3) has recently been identified in mitochondria (MITO) of cardiomyocytes (mSTAT3). In STAT3-/- cells, the activities of MITO complexes I and II of the electron transport chain (ETC) were significantly reduced suggesting that mSTAT3 is required for optimal ETC function. In the heart, mSTAT3 activity is modulated by the heat shock protein H11 kinase (H11K) previously shown to be reduced in MITO of dogs with HF. We showed that long-term (3 months) therapy with elamipretide (ELA, Bendavia TM ), a novel MITO-targeting peptide, improves LV systolic function and to normalize MITO respiration, rate of ATP synthesis and H11K levels in MITO of LV cardiomyocytes of dogs with heart failure (HF). Hypothesis: This study tested the hypothesis that the level of mSTAT3 is reduced in LV myocardium of dogs with HF and that long-term therapy with ELA restores levels of mSTAT3. Methods: LV tissue was obtained from 14 dogs with microembolization-induced HF (LV ejection fraction ~30%) randomized to 3 months therapy with subcutaneous injections of ELA (0.5 mg/kg once daily, n=7) or saline (Control, n=7). LV tissue from 6 normal dogs was used for comparison. Protein levels of mSTAT3 and porin; the latter a MITO protein unchanged in HF (internal control), were determined in isolated MITO fractions from LV tissue using by Western blotting coupled with chemiluminescence. Protein band intensities were quantified in densitometric units (du). Results: Protein levels of porin was similar in all 3 study groups (NL:0.24±0.01; Control: 0.22±0.01; ELA: 0.23±0.01 du). Levels of mSTAT3 were 0.82±0.05 du in NL, decreased to 0.29±0.03 du in Controls (p&lt;0.05 vs. NL) and were partially restored by ELA (0.53±0.05, p&lt;0.05 vs. Control). Levels of mSTAT3 normalized to porin were 3.6±0.3 du in NL, decreased to 1.3±0.1 in Controls (p&lt;0.05 vs. NL) and were restored to near normal levels following treatment with ELA (2.3±0.2, p&lt;0.05 vs. Control). Conclusions: mSTAT3 level is reduced in MITO of from LV myocardium of HF dogs and restored after chronic therapy with ELA. Normalization of mSTAT3 by ELA likely contributed to the observed improvement in MITO function following therapy with ELA in dogs with chronic HF.
Effects of restrictions to Income Support on health of lone mothers in the UK: a natural experiment study
Authors: Srinivasa Vittal Katikireddi, Oarabile R Molaodi, Marcia Gibson, Ruth Dundas, Peter Craig
Journal: The Lancet Public Health (2018)

In the UK, lone parents must seek work as a condition of receiving welfare benefits once their youngest child reaches a certain age. Since 2008, the lower age limit at which these Lone Parent Obligations (LPO) apply has been reduced in steps. We used data from a nationally representative, longitudinal, household panel study to analyse the health effects of increased welfare conditionality under LPO.From the Understanding Society survey, we used data for lone mothers who were newly exposed to LPO when the age cutoff was reduced from 7 to 5 years in 2012 (intervention group 1) and from 10 to 7 years in 2010 (intervention group 2), as well as lone mothers who remained unexposed (control group 1) or continuously exposed (control group 2) at those times. We did difference-in-difference analyses that controlled for differences in the fixed characteristics of participants in the intervention and control groups to estimate the effect of exposure to conditionality on the health of lone mothers. Our primary outcome was the difference in change over time between the intervention and control groups in scores on the Mental Component Summary (MCS) of the 12-item Short-Form Health Survey (SF-12).The mental health of lone mothers declined in the intervention groups compared with the control groups. For intervention group 1, scores on the MCS decreased by 1·39 (95% CI -1·29 to 4·08) compared with control group 1 and by 2·29 (0·00 to 4·57) compared with control group 2. For intervention group 2, MCS scores decreased by 2·45 (-0·57 to 5·48) compared with control group 1 and by 1·28 (-1·45 to 4·00) compared with control group 2. When pooling the two intervention groups, scores on the MCS decreased by 2·13 (0·10 to 4·17) compared with control group 1 and 2·21 (0·30 to 4·13) compared with control group 2.Stringent conditions for receiving welfare benefits are increasingly common in high-income countries. Our results suggest that requiring lone parents with school-age children toseek work as a condition of receiving welfare benefits adversely affects their mental health.UK Medical Research Council, Scottish Government Chief Scientist Office, and National Health Service Research Scotland.
Abstract 5504: TRAF3 acts as a tumor suppressor through modulation of TP53 and RB in human papillomavirus associated head and neck squamous cell carcinomas
Authors: Tony Wayne Chen, Jialing Zhang, Xinping Yang, Zhong Chen, Carter Van Waes
Journal: Cancer Research (2018)

Abstract The number of human papillomavirus-associated (HPV+) head and neck squamous cell carcinoma (HNSCC) cases has increased sharply in recent years, especially among tonsillar and oropharyngeal cancers. The Cancer Genome Atlas (TCGA) network identified novel loss-of-function genomic alterations of TNF receptor-associated factor 3 (TRAF3) in a subset of HPV+ HNSCC specimens. Previously, most studies of TRAF3 function are from the immune system and lymphoid malignancies, where TRAF3 has been implicated as a ring-finger E3 ubiquitin ligase that promotes anti-viral immunity, while inhibiting alternative NF-κB signaling by which DNA viruses can transform lymphoid cells. However, the function of TRAF3 and the mechanisms by which TRAF3 deficiency contributes to tumorigenesis are largely unknown. To explore the potential mechanisms of TRAF3 defects observed in the tumor subset identified by TCGA, we surveyed a panel of HPV+ HNSCC cell lines, and identified lines with lower steady-state protein levels of TRAF3 than normal oral keratinocytes. Functional studies show that TRAF3 expression leads to suppression of oncogenic phenotypes, including decreased alternative NF-κB signaling, cell proliferation, colony formation, and cell migration. Additionally, restoring TRAF3 increased anti-viral cytokine interferon alpha (IFNA) expression, and sensitivity to chemotherapy agent cisplatin. The anti-proliferative activity of TRAF3 was partially mediated by restoration of expression of classical tumor suppressor genes, TP53 and RB, which are degraded in HPV+ cancers. TRAF3 re-expression increased the steady-state protein levels of TP53 and gene expression of TP53AIP, which mediates cell cycle arrest and apoptosis. Knockdown of TP53 in TRAF3 transfected cell lines partially reversed the slowed cell growth rate, supporting the contribution of TP53 to TRAF3 mediated growth inhibition. TRAF3 expression also increased RB protein expression and decreased RB regulated transcription factor E2F1, which regulates cellular genes involved in cell proliferation and DNA synthesis. In conclusion, we have revealed a novel role whereby TRAF3 loss leads to enhanced HPV mediated repression of the TP53 and RB tumor suppressors that control cell growth and cell death in HPV+ HNSCCs. (Supported by NIDCD intramural project ZIA-DC-000016, 73 and 74) Citation Format: Tony Wayne Chen, Jialing Zhang, Xinping Yang, Zhong Chen, Carter Van Waes. TRAF3 acts as a tumor suppressor through modulation of TP53 and RB in human papillomavirus associated head and neck squamous cell carcinomas [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 5504.
Author Correction: Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes
Authors: Bjoern Chapuy, Chip Stewart, Andrew J. Dunford, Jaegil Kim, Atanas Kamburov, Robert A. Redd, Mike S. Lawrence, Margaretha G. M. Roemer, Amy J. Li, Marita Ziepert, Annette M. Staiger, Jeremiah A. Wala, Matthew D. Ducar, Ignaty Leshchiner, Ester Rheinbay, Amaro Taylor-Weiner, Caroline A. Coughlin, Julian M. Hess, Chandra S. Pedamallu, Dimitri Livitz, Daniel Rosebrock, Mara Rosenberg, Adam A. Tracy, Heike Horn, Paul van Hummelen, Andrew L. Feldman, Brian K. Link, Anne J. Novak, James R. Cerhan, Thomas M. Habermann, Reiner Siebert, Andreas Rosenwald, Aaron R. Thorner, Matthew L. Meyerson, Todd R. Golub, Rameen Beroukhim, Gerald G. Wulf, German Ott, Scott J. Rodig, Stefano Monti, Donna S. Neuberg, Markus Loeffler, Michael Pfreundschuh, Lorenz Trümper, Gad Getz, Margaret A. Shipp
Journal: Nature Medicine (2018)
Critical Role for the Microbiota in CX3CR1+ Intestinal Mononuclear Phagocyte Regulation of Intestinal T Cell Responses
Authors: Myunghoo Kim, Carolina Galan, Andrea A. Hill, Wan-Jung Wu, Hannah Fehlner-Peach, Hyo Won Song, Deborah Schady, Matthew L. Bettini, Kenneth W. Simpson, Randy S. Longman, Dan R. Littman, Gretchen E. Diehl
Journal: Immunity (2018)
Update of Recommendations for Use of Once-Weekly Isoniazid-Rifapentine Regimen to Treat Latent<i>Mycobacterium tuberculosis</i>Infection
Authors: Andrey S. Borisov, Sapna Bamrah Morris, Gibril J. Njie, Carla A. Winston, Deron Burton, Stefan Goldberg, Rachel Yelk Woodruff, Leeanna Allen, Philip LoBue, Andrew Vernon
Journal: MMWR Morbidity and Mortality Weekly Report (2018)

Treatment of latent tuberculosis infection (LTBI) is critical to the control and elimination of tuberculosis disease (TB) in the United States. In 2011, CDC recommended a short-course combination regimen of once-weekly isoniazid and rifapentine for 12 weeks (3HP) by directly observed therapy (DOT) for treatment of LTBI, with limitations for use in children aged <12 years and persons with human immunodeficiency virus (HIV) infection (1). CDC identified the use of 3HP in those populations, as well as self-administration of the 3HP regimen, as areas to address in updated recommendations. In 2017, a CDC Work Group conducted a systematic review and meta-analyses of the 3HP regimen using methods adapted from the Guide to Community Preventive Services. In total, 19 articles representing 15 unique studies were included in the meta-analysis, which determined that 3HP is as safe and effective as other recommended LTBI regimens and achieves substantially higher treatment completion rates. In July 2017, the Work Group presented the meta-analysis findings to a group of TB experts, and in December 2017, CDC solicited input from the Advisory Council for the Elimination of Tuberculosis (ACET) and members of the public for incorporation into the final recommendations. CDC continues to recommend 3HP for treatment of LTBI in adults and now recommends use of 3HP 1) in persons with LTBI aged 2-17 years; 2) in persons with LTBI who have HIV infection, including acquired immunodeficiency syndrome (AIDS), and are taking antiretroviral medications with acceptable drug-drug interactions with rifapentine; and 3) by DOT or self-administered therapy (SAT) in persons aged ≥2 years.
Abstract CT092: Effect of tumor treating fields in children with recurrent or progressive high-grade glioma and ependymoma; Pediatric Brain Tumor Consortium PBTC048
Authors: Stewart Goldman, Arzu Onar-Thomas, Ira Dunkel, Eugene Hwang
Journal: Cancer Research (2018)

Abstract Background: Current treatment regimens show poor prognosis in recurrent or progressive pediatric CNS tumors. Children with high-grade gliomas (HGG) after progression cannot be cured, with reported median survival &amp;lt;1-2 years. Overall survival (OS) of pediatric recurrent/progressive ependymoma is also poor. Tumor Treating Fields (TTFields) is an anti-mitotic cancer therapy for the treatment of recurrent (supratentorial) glioblastoma (GB). A phase 3 clinical trial in adults with newly-diagnosed GB was stopped early due to significant improvements of event-free (EFS) and OS in patients receiving TTFields in conjunction with temozolomide. A separate phase 3 trial comparing TTFields monotherapy with physician's choice chemotherapy in adults with recurrent GB demonstrated comparable OS and improved quality-of-life (QoL). Methods: This multicenter feasibility trial [NCT03033992] will examine the feasibility and device-related toxicity of TTFields in children aged 5-21 years with supratentorial HGG and ependymoma. The secondary objectives include: response rate, event-free survival, compliance and QoL. To establish feasibility Optune device will need to be worn ≥18 hours/day for at least 23/28 days of cycle one. Patients will have a brain MRI with/without contrast performed prior to therapy, after cycles 2, 4, 6, 9, then every 3 cycles thereafter until time of progression or completion of treatment. Treatment may continue up to 26 cycles based on observed benefit and safety. A sample size of 20 patients is planned with an interim analysis after the first 11 patients. Kaplan-Meier estimates of EFS for all eligible patients will be provided separately for the HGG and ependymoma cohorts. The rates of confirmed sustained objective responses (CR+PR) observed during treatment will be estimated. All PROMIS and Neuro-QoL scores will be reported using T-score matrix (mean=50; SD=10). The projected accrual rate is 1.5-2.5 patients per month with a follow-up for 2 years. The study is currently accruing patients. Citation Format: Stewart Goldman, Arzu Onar-Thomas, Ira Dunkel, Eugene Hwang. Effect of tumor treating fields in children with recurrent or progressive high-grade glioma and ependymoma; Pediatric Brain Tumor Consortium PBTC048 [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr CT092.